Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지

Type 3 Gastric Neuroendocrine Neoplasm Clinical Features: A Multicenter Study in Korea

  • Kyong Joo Lee (Department of Internal Medicine, Yonsei University Wonju College of Medicine) ;
  • Hee Man Kim (Department of Internal Medicine, Yonsei University Wonju College of Medicine) ;
  • Sang Kil Lee (Department of Internal Medicine, Yonsei Institute of Gastroenterology, Yonsei University College of Medicine) ;
  • Ho Sun Choi (Department of Internal Medicine, Hanyang University College of Medicine) ;
  • Jie-Hyun Kim (Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Seun Ja Park (Department of Internal Medicine, Kosin University College of Medicine) ;
  • Sung Chul Park (Department of Internal Medicine, Kangwon National University School of Medicine) ;
  • Byung Ik Jang (Department of Internal Medicine, Yeungnam University College of Medicine) ;
  • Jin Tae Jung (Department of Internal Medicine, Catholic University of Daegu School of Medicine) ;
  • Tae Joo Jeon (Department of Internal Medicine, Inje University Sanggye Paik Hospital, Inje University College of Medicine) ;
  • Jong Hun Lee (Department of Internal Medicine, Dong-A University College of Medicine) ;
  • Jae Kyu Sung (Department of Internal Medicine, Chungnam National University School of Medicine) ;
  • Semi Park (Health Promotion Center, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Yoon Jae Kim (Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Jae Hee Cho (Department of Internal Medicine, Gachon University Gil Medical Center)
  • Received : 2017.07.17
  • Accepted : 2017.12.03
  • Published : 2017.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The aim of this study was to investigate clinicopathologic features of type 3 gastric neuroendocrine neoplasm (NEN) by treatment modality. Methods: The Korean Society of Gastrointestinal Cancer conducted the Korean Gastroenteropancreatic Neuroendocrine Tumor Registry, a retrospective registry database of gastroenteropancreatic neuroendocrine tumors from 16 hospitals in Korea. The normal serum gastrin level range was defined as <100 pg/mL, and gastric NEN patients with normal gastrin level were selected for analysis. Results: Among 358 patients with gastric NEN, 21 (5.9%) patients were classified with type 3 gastric NEN. The median age was 53 years (range 30-74). According to the WHO 2010 classification, 13 (61.9%) patients had grade 1, and 8 (38.1%) patients had grade 2 or 3. Endoscopic treatment was performed in 14 (66.7%) patients, and surgery was performed in 7 (33.3%) patients. The tumor size was smaller in the endoscopic treatment group than in the surgery group (0.6 cm vs 1.3 cm, p=0.006). After treatment, there was one recurrence in the surgery group. Conclusion: In small size Type 3 gastric NEN, endoscopic treatment was associated with a good prognosis, compared to surgery. Thus, endoscopic treatment can be used an alternative modality in selected cases of type 3 gastric NEN.

Keywords

Acknowledgement

This study was conducted as a part of the Korean Gastroenteropancreatic Neuroendocrine Tumor Registry research projects of "The Korean Society of Gastrointestinal Cancer (KSGC)".

References

  1. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004;99:23-32.
  2. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
  3. Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993;104:994-1006.
  4. Burkitt MD, Pritchard DM. Review article: Pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther 2006;24:1305-1320.
  5. Norton JA, Melcher ML, Gibril F, Jensen RT. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery 2004;136:1267-1274.
  6. Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G, Grimelius L. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005;242:64-73.
  7. Rappel S, Altendorf-Hofmann A, Stolte M. Prognosis of gastric carcinoid tumours. Digestion 1995;56:455-462.
  8. Delle Fave G, Capurso G, Milione M, Panzuto F. Endocrine tumours of the stomach. Best Pract Res Clin Gastroenterol 2005;19:659-673.
  9. Kwon YH, Jeon SW, Kim GH, et al. Long-term follow up of endoscopic resection for type 3 gastric NET. World J Gastroenterol 2013;19:8703-8708.
  10. Scherubl H, Cadiot G, Jensen RT, Rosch T, Stolzel U, Kloppel G. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy 2010;42:664-671.
  11. Dakin GF, Warner RR, Pomp A, Salky B, Inabnet WB. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol 2006;93:368-372.
  12. Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol 2003;12:153-172.
  13. Thomas D, Tsolakis AV, Grozinsky-Glasberg S, et al. Longterm follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. Eur J Endocrinol 2013;168:185-193.
  14. Merola E, Sbrozzi-Vanni A, Panzuto F, et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology 2012;95:207-213.
  15. La Rosa S, Inzani F, Vanoli A, et al. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol 2011;42:1373-1384.
  16. Spinelli P, Cerrai FG, Casella G, Pizzetti P. Endoscopic treatment of gastric carcinoids. Minerva Chir 1994;49:271-273.
  17. Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996;20:168-172.
  18. Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012;95:157-176.
  19. Basuroy R, Srirajaskanthan R, Prachalias A, Quaglia A, Ramage JK. Review article: the investigation and management of gastric neuroendocrine tumours. Aliment Pharmacol Ther 2014;39:1071-1084.
  20. Plockinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004;80:394-424.
  21. Massironi S, Sciola V, Spampatti MP, Peracchi M, Conte D. Gastric carcinoids: between underestimation and overtreatment. World J Gastroenterol 2009;15:2177-2183.
  22. Karanicolas PJ, Graham D, Gonen M, Strong VE, Brennan MF, Coit DG. Quality of life after gastrectomy for adenocarcinoma: a prospective cohort study. Ann Surg 2013;257:1039-1046.
  23. Wu CW, Chiou JM, Ko FS, et al. Quality of life after curative gastrectomy for gastric cancer in a randomised controlled trial. Br J Cancer 2008;98:54-59.
  24. Kim BS, Oh ST, Yook JH, et al. Typical carcinoids and neuroendocrine carcinomas of the stomach: differing clinical courses and prognoses. Am J Surg 2010;200:328-333.
  25. Kim BS, Park YS, Yook JH, Oh ST, Kim BS. Differing Clinical Courses and Prognoses in Patients With Gastric Neuroendocrine Tumors Based on the 2010-WHO Classification Scheme. Medicine (Baltimore) 2015;94:e1748.